Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
SEATTLE, Aug. 14, 2017 -- Atossa Genetics Inc. (NASDAQ:ATOS) today announced Second Quarter ended June 30, 2017 financial results and provided an update on recent company developments.
Steve Quay, President and CEO, commented, “We have reached an important milestone by completing enrollment in both the topical and oral arms of our Phase 1 Endoxifen study. We look forward to announcing preliminary top-line results from the topical arm of our endoxifen study later this quarter.”
Recent Corporate Developments
Atossa’s important recent developments include the following:
- Completed enrollment in both the oral and topical arms of our proprietary Endoxifen Phase 1 dose escalation study.
- Completed capital raise of approximately $4.4 million gross proceeds.
- Eliminated warrants to purchase approximately 3 million shares of common stock through cashless warrant exercises on June 30 and subsequent to that eliminated warrants to purchase approximately an additional 1.6 million shares of common stock through cash exercises.
- Received multiple positive interim safety assessments from the safety committee on our proprietary Endoxifen Phase 1 dose escalation study.
- Completed the transfer of the Fulvestrant Microcatheter Phase 2 study to Montefiore Medical Center.
Q2 2017 Financial Results
We are in the research and development phase and we did not generate revenue for the three and six months ended June 30, 2017.
Total operating expenses were approximately $1.9 million and $3.6 million for the three and six months ended June 30, 2017, respectively, consisting of general and administrative (G&A) expenses of approximately $1.1 million and $2.2 million, respectively, and research and development (R&D) expenses of approximately $0.8 million and $1.4 million, respectively. Total operating expenses were approximately $1.7 million and $4.0 million for the three and six months ended June 30, 2016, respectively, consisting of G&A expense of approximately $1.6 million and $3.7 million, respectively, and R&D expenses of $0.2 million and $0.3 million, respectively.
About Atossa Genetics
Atossa Genetics Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa’s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
ATOSSA GENETICS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
| June 30, | December 31, | |||||||
| 2017 | 2016 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 3,690,023 | $ | 3,027,962 | ||||
| Restricted cash | 55,000 | 55,000 | ||||||
| Prepaid expenses | 228,370 | 171,601 | ||||||
| Other accounts receivable | 2,736 | |||||||
| Total current assets | 3,976,129 | 3,254,563 | ||||||
| Furniture and equipment, net | 18,989 | 55,119 | ||||||
| Intangible assets, net | 585,683 | 640,440 | ||||||
| Other assets | 128,577 | 194,250 | ||||||
| Total assets | $ | 4,709,378 | $ | 4,144,372 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 495,811 | $ | 254,320 | ||||
| Accrued expenses | 44,017 | 16,964 | ||||||
| Payroll liabilities | 482,420 | 769,899 | ||||||
| Common stock warrant liability | 864,371 | |||||||
| Other current liabilities | 19,157 | 6,083 | ||||||
| Total current liabilities | 1,905,776 | 1,047,266 | ||||||
| Commitments and contingencies (note 13) | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock - $.001 par value; 10,000,000 shares authorized, consisting of: | ||||||||
| Series A convertible preferred stock- $.001 par value; 4,000 and 0 shares authorized, and 839 and 0 shares issued and outstanding, as of June 30, 2017 and December 31, 2016, respectively | 1 | |||||||
| Additional paid in capital- Series A convertible preferred stock | 774,977 | |||||||
| Common stock - $.015 par value; 75,000,000 shares authorized, 10,032,410 and 3,786,913 shares issued and outstanding, as of June 30, 2017 and December 31, 2016, respectively | 150,486 | 56,804 | ||||||
| Additional paid-in capital | 63,126,929 | 60,344,050 | ||||||
| Accumulated deficit | (61,248,791 | ) | (57,303,748 | ) | ||||
| Total stockholders’ equity | 2,803,602 | 3,097,106 | ||||||
| Total liabilities and stockholders’ equity | $ | 4,709,378 | $ | 4,144,372 | ||||
ATOSSA GENETICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
| For the Three Months Ended June 30, | For The Six Months Ended June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 824,094 | $ | 168,992 | $ | 1,368,396 | $ | 318,963 | ||||||||
| General and administrative | 1,072,169 | 1,553,391 | 2,214,712 | 3,730,960 | ||||||||||||
| Total operating expenses | 1,896,263 | 1,722,383 | 3,583,108 | 4,049,923 | ||||||||||||
| Operating loss | (1,896,263 | ) | (1,722,383 | ) | (3,583,108 | ) | (4,049,923 | ) | ||||||||
| Change in fair value of common stock warrants | (152,447 | ) | (152,447 | ) | ||||||||||||
| Warrant financing expense | (192,817 | ) | (192,817 | ) | ||||||||||||
| Other income (expense), net | 38 | (16,671 | ) | |||||||||||||
| Loss before income taxes | (2,241,489 | ) | (1,722,383 | ) | (3,945,043 | ) | (4,049,923 | ) | ||||||||
| Income taxes | ||||||||||||||||
| Net loss | $ | (2,241,489 | ) | $ | (1,722,383 | ) | $ | (3,945,043 | ) | $ | (4,049,923 | ) | ||||
| Deemed dividends attributable to Series A Preferred Stock | (2,568,132 | ) | (2,568,132 | ) | ||||||||||||
| Net loss applicable to common stockholders | $ | (4,809,621 | ) | $ | (1,722,383 | ) | $ | (6,513,175 | ) | $ | (4,049,923 | ) | ||||
| Loss per common share - basic and diluted | $ | (0.64 | ) | $ | (0.67 | ) | $ | (1.15 | ) | $ | (1.63 | ) | ||||
| Weighted average shares outstanding, basic and diluted | 7,476,046 | 2,587,871 | 5,641,671 | 2,485,853 | ||||||||||||
Atossa Genetics Company Contact: Atossa Genetics Inc. Kyle Guse CFO and General Counsel (O) 800-351-3902 [email protected] Investor Relations Contact Scott Gordon CorProminence LLC 377 Oak Street Concourse 2 Garden City, NY 11530 Office: 516.222.2560 [email protected]
